VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Valneva SE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026

$5.51−0.10 (-1.78%)

Close on Oct 19, 2026

Valneva SE income statement

Annual Quarterly TTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	175	170	154	361	348	110	126
Cost of Revenue	107	99	101	324	188	54	53
Gross Profit	68	71	53	37	160	56	73
Research & Development	85	74	60	105	173	84	38
Selling, General & Admin	–	–	–	–	48	28	18
Selling & Marketing	–	–	–	–	24	18	24
General & Administrative	–	–	–	–	0.30	0.30	–
Advertising Expenses	9.04	17	13	7.34	2.18	2.50	–
Operating Expenses	267	268	257	487	432	185	–
Operating Income	-82	13	-82	-113	-61	-55	-0.81
Interest Expense	42	24	23	19	17	11	3.08
Interest & Investment Income	2.64	2.36	1.21	0.26	0.25	0.52	1.45
Income from Equity Investments	–	–	–	–	-0.01	-0.13	1.57
Asset Impairment Charges	–	–	–	23	0	–	–
Pretax Income	-114	-11	-99	-145	-70	-65	-0.87
Income Tax Expense	1.07	0.76	2.80	-1.54	3.45	-0.91	0.87
Net Income incl. Noncontrolling Interests	-115	-12	-101	-143	-73	-64	-1.74
Net Income	–	–	–	–	-61	-55	-0.81
Net Income to Common	-115	-12	-101	-143	-73	-64	-1.74
EPS (Basic)(per share)	-0.68	-0.08	-0.73	-1.24	-0.75	-0.71	-0.02
EPS (Diluted)(per share)	-0.68	-0.08	-0.73	-1.24	-0.75	-0.71	-0.02
Shares Outstanding (Basic, Weighted)(shares)	168	146	139	115	98	91	92
Shares Outstanding (Diluted, Weighted)(shares)	168	146	139	115	98	91	92
EBITDA	-60	33	-65	-92	-47	-45	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 16.4%
Operating margin: -80.5%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 2.16
Debt to equity: –
Debt to assets: 47.4%
Cash to current liabilities: 117.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.